CoChat

Choosing the Right Tool for Genetic Engineering: Clinical Lessons from Chimeric Antigen Receptor-T Cells

Irving, Melita, Lanitis, Evripidis, Migliorini, Denis, Ivics, Zoltán, Guedan, Sonia · 2021 · Human Gene Therapy
Cited by 113

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

T cell modification with genes that encode chimeric antigen receptors (CAR-T cells) has shown tremendous promise for the treatment of B cell malignancies. The successful translation of CAR-T cell therapy to other tumor types, including solid tumors, is the next big challenge. As the field advances from second- to next-generation CAR-T cells comprising multiple genetic modifications, more sophisticated methods and tools to engineer T cells are being developed. Viral vectors, especially γ-retroviruses and lentiviruses, are traditionally used for CAR-T cell engineering due to their high transduction efficiency. However, limited genetic cargo, high costs of production under good manufacturing practice (GMP) conditions, and the high regulatory demands are obstacles for widespread clinical translation. To overcome these limitations, different nonviral approaches are being explored at a preclinical or clinical level, including transposon/transposase systems and mRNA electroporation and nonintegrating DNA nanovectors. Genome editing tools that allow efficient knockout of particular genes and/or site-directed integration of the CAR and/or other transgenes into the genome are also being evaluated for CAR-T cell engineering. In this review, we discuss the development of viral and nonviral vectors used to generate CAR-T cells, focusing on their advantages and limitations. We also discuss the lessons learned from clinical trials using the different genetic engineering tools, with special focus on safety and efficacy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1089/hum.2021.173

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Research works printed but not linked: 67

  1. 10.1146/annurev-immunol-042718-041407 · DOI · Paper page
  2. 10.1056/NEJMra1706169 · DOI · Paper page
  3. 10.1016/j.copbio.2020.01.009 · DOI
  4. 10.1038/s41573-021-00155-y · DOI · Paper page
  5. 10.1038/s41573-021-00155-y · DOI · Paper page
  6. 10.1016/j.omtm.2018.12.009 · DOI · Paper page
  7. 10.3390/biomedicines4020009 · DOI
  8. 10.1126/sciadv.abf1333 · DOI · Paper page
  9. 10.2174/1566523054546224 · DOI · Paper page
  10. 10.1097/CJI.0b013e3182187600 · DOI · Paper page
  11. 10.1128/JVI.73.4.2886-2892.1999 · DOI · Paper page
  12. 10.1056/NEJM199008303230904 · DOI · Paper page
  13. 10.1126/scitranslmed.3003761 · DOI · Paper page
  14. 10.1016/j.ymthe.2017.10.012 · DOI · Paper page
  15. 10.1089/hum.2005.16.457 · DOI · Paper page
  16. 10.1182/blood-2017-02-769208 · DOI · Paper page
  17. 10.1089/hum.2012.203 · DOI · Paper page
  18. 10.1182/blood-2007-12-128751 · DOI · Paper page
  19. 10.1038/s43018-021-00207-7 · DOI
  20. 10.1172/JCI130144 · DOI · Paper page
  21. 10.1073/pnas.1919259117 · DOI · Paper page
  22. 10.1038/nmeth.1332 · DOI · Paper page
  23. 10.1002/bies.202000136 · DOI
  24. 10.1073/pnas.36.6.344 · DOI · Paper page
  25. 10.1016/S0092-8674(00)80436-5 · DOI · Paper page
  26. 10.1038/mt.2016.11 · DOI · Paper page
  27. 10.1172/JCI86721 · DOI · Paper page
  28. 10.1158/0008-5472.CAN-07-5600 · DOI · Paper page
  29. 10.1016/j.surg.2019.05.047 · DOI
  30. 10.18632/oncotarget.9955 · DOI
  31. 10.1016/j.ymthe.2020.05.021 · DOI
  32. 10.1172/JCI138473 · DOI · Paper page
  33. 10.1038/mt.2016.51 · DOI
  34. 10.1089/hum.2017.136 · DOI
  35. 10.1016/j.jcyt.2019.03.562 · DOI
  36. 10.1182/blood-2018-99-111419 · DOI · Paper page
  37. 10.1182/blood-2019-129562 · DOI
  38. 10.1089/hum.2008.068 · DOI · Paper page
  39. 10.1158/0008-5472.CAN-10-2880 · DOI · Paper page
  40. 10.18632/oncotarget.5029 · DOI · Paper page
  41. 10.1158/2326-6066.CIR-13-0170 · DOI · Paper page
  42. 10.1080/2162402X.2020.1792625 · DOI
  43. 10.1111/exd.13678 · DOI
  44. 10.3109/10428194.2011.634048 · DOI · Paper page
  45. 10.1038/mt.2016.146 · DOI · Paper page
  46. Cummins KD, , Frey N, , Nelson AM, et al. Treating relapsed/refractory (RR) AML with biodegradable anti-CD123 CAR modified T cells. Blood, 2017; 130:1359.
  47. 10.1182/blood-2018-03-837609 · DOI · Paper page
  48. 10.1158/2326-6066.CIR-13-0006 · DOI · Paper page
  49. 10.1053/j.gastro.2018.03.029 · DOI · Paper page
  50. 10.1158/2326-6066.CIR-17-0189 · DOI · Paper page
  51. 10.1093/nar/gky289 · DOI
  52. 10.1146/annurev-genet-110410-132435 · DOI · Paper page
  53. 10.1038/s41580-019-0131-5 · DOI · Paper page
  54. 10.1126/science.1231143 · DOI · Paper page
  55. 10.1126/science.1232033 · DOI · Paper page
  56. 10.1126/science.1225829 · DOI · Paper page
  57. 10.1038/cr.2016.142 · DOI · Paper page
  58. 10.1182/blood-2017-01-761320 · DOI · Paper page
  59. 10.1080/2162402X.2017.1407898 · DOI
  60. 10.1158/1538-7445.AM2020-CT052 · doi:10.1158/1538-7445.am2020-ct052
  61. 10.1038/s41591-020-0840-5 · DOI · Paper page
  62. 10.1038/s41423-021-00749-x · DOI · Paper page
  63. 10.1016/j.ymthe.2017.02.005 · DOI · Paper page
  64. 10.15252/emmm.201809158 · DOI · Paper page
  65. 10.1038/s41408-021-00508-1 · DOI · Paper page
  66. 10.1016/S0140-6736(20)32334-5 · DOI · Paper page
  67. 10.1158/1078-0432.CCR-20-3863 · DOI · Paper page

Cited by

Metadata

Authors
Irving, M., Lanitis, E., Migliorini, D., Ivics, Z., & Guedan, S.
Affiliations
  • Department of Oncology, Ludwig Institute for Cancer Research Lausanne, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Department of Oncology, Geneva University Hospitals, Geneva, Switzerland.
  • Transposition and Genome Engineering, Division of Medical Biotechnology, Paul Ehrlich Institute, Langen, Germany.
  • Department of Hematology and Oncology, Hospital Clinic, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
Venue
Human Gene Therapy
Published
2021-10
Volume
32
Issue
19-20
Pages
1044-1058
ISSN
  • 1043-0342
  • 1557-7422
Cited by
113
References
21
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.